New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
07:06 EDTMYGNMyriad Genetics Prolaris test predicts risk of prostate cancer recurrence
Myriad Genetics announced that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical prostatectomy. The study entitled "Validation of a panel of cell cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," concluded that the Prolaris test effectively stratified men by risk of biochemical recurrence.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
16:34 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
11:09 EDTMYGNMyriad Genetics advises prior BRACAnalysis news release be disregarded
Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
10:16 EDTMYGNMyriad Genetics has a conference call hosted by JPMorgan
Subscribe for More Information
05:48 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
April 4, 2014
11:07 EDTMYGNMyriad Genetics price target raised to $42 from $34 at Piper Jaffray
Piper Jaffray raised its price target for Myriad Genetics shares to $42 to reflect CMS' recent decision to increase BRCA reimbursement. The firm keeps an Overweight rating on the stock.
10:02 EDTMYGNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:48 EDTMYGNMyriad Genetics upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
06:46 EDTMYGNMyriad Genetics upgraded to Buy from Neutral at Mizuho
April 3, 2014
07:37 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho raised Myriad's price target to $40 from $28 following the better than expected CMS pricing for BRCA testing. Shares are Neutral rated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use